Mixed lichenoid and psoriasiform drug eruption induced by rifampicin.

Xia Feng, Xin Ye, Jixiang Xu, Changqiang Li

The Australasian journal of dermatology 2020 May

filter terms:

all
compound
phenotype
FDA drugs
show more »
show less «

Rifampicin is an essential first line anti-tuberculosis drug. However, several cases of adverse reactions associated with this drug have been reported, the most common of which are cutaneous drug reactions. We report a case of mixed lichenoid and psoriasiform drug eruption induced by rifampicin. © 2019 The Australasian College of Dermatologists.

Citation

Xia Feng, Xin Ye, Jixiang Xu, Changqiang Li. Mixed lichenoid and psoriasiform drug eruption induced by rifampicin. The Australasian journal of dermatology. 2020 May;61(2):e231-e233